DongKoo Bio & Pharma
Daily close in US$ at the latest USD/KRW close. Source: KRX via FinanceDataReader.
DongKoo Bio & Pharma makes and supplies pharmaceutical products, medicines used in everyday medical treatment, to the Korean healthcare market.
It is listed on KOSDAQ, South Korea's technology and small-cap stock exchange. The filing's table of contents covers a broad range of products and services, research and development activity, and production facilities, suggesting the company operates across multiple pharmaceutical product lines rather than a single narrow focus.
Summary is AI-generated and may contain errors · figures from DART filings
DongKoo Bio & Pharma in five facts
What does DongKoo Bio & Pharma do?
DongKoo Bio & Pharma makes and supplies pharmaceutical products, medicines used in everyday medical treatment, to the Korean healthcare market.
Where is DongKoo Bio & Pharma listed and in which sector?
DongKoo Bio & Pharma (Korean name: 동구바이오제약) trades under KRX code 006620 on KOSDAQ, the Korea Exchange's board for smaller and growth companies. It is classified in the Health Care sector, Pharmaceuticals.
How large is DongKoo Bio & Pharma?
Its market capitalisation was US$73.3M on 2026-10-21, which puts it in this site's small-cap group. US$ amounts are converted from won at 1 USD ≈ ₩1,325 (2026-10-21).
What were DongKoo Bio & Pharma's latest annual revenue and operating profit?
For fiscal year 2025, DongKoo Bio & Pharma reported revenue of US$183.2M, operating profit of US$7M and net income of US$37.9M, per its annual report on DART (data retrieved from DART on 2026-10-02). Revenue was down 2.6% on the previous year.
Where does this data come from?
Financial statements and filings come from DART, Korea's official corporate-filing system. Share prices, market capitalisation and trading status come from KRX. Company summaries are AI-generated from the filings and may contain errors; financial figures are mapped directly from DART.
Data sources and last updated
- Filings and financial statements
- DART (dart.fss.or.kr), Korea's official corporate-filing system
- Prices, market cap, trading status
- KRX (Korea Exchange), via FinanceDataReader
- Latest annual financials
- Fiscal year 2025, data retrieved from DART on 2026-10-02
- Share price and market cap
- Close of 2026-10-21
- Currency
- US$, converted from won at 1 USD ≈ ₩1,325 (2026-10-21 close)
- Company data updated
- 2026-10-21
- Company summary
- AI-generated from filings; may contain errors. Information only, not investment advice.
- Report on large shareholdings (5% rule) (standard)Oct 19
- Report on large shareholdings (5% rule) (standard)Oct 8
- [Amended] Material event report (business suspension)Oct 8
- Report on large shareholdings (5% rule) (standard)Sep 15
- [Amended] Material event report (business suspension)Sep 10
- Report on large shareholdings (5% rule) (standard)Sep 2
- Change of 30% or more in revenue or profit/loss structure (15% for large companies)
DongKoo Bio & Pharma reported consolidated results for FY2025: revenue of US$162M (−2.6% year on year), operating profit of US$6.16M (−27.1% year on year) and net income of US$33.4M (+2420.2% year on year).
Earnings · Mar 16 - Cash/in-kind dividend decision
DongKoo Bio & Pharma declared a cash dividend of US$0.08 per share, equal to about 2.2% of the recent share price.
Dividend · Mar 16